Erschienen in:
01.03.2007 | Case Report
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
verfasst von:
Lisa M. Neff, Michelle Weil, Alan Cole, Thomas R. Hedges, William Shucart, Donald Lawrence, Jay-Jiguang Zhu, Arthur S. Tischler, Ronald M. Lechan
Erschienen in:
Pituitary
|
Ausgabe 1/2007
Einloggen, um Zugang zu erhalten
Abstract
Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.